Opinion|Videos|June 21, 2024
Examining Key Data from the FLAURA2 and MIRAPOSA Trials
A renowned lung cancer pharmacy specialist presents the efficacy and safety data from the phase 3 FLAURA2 trial, emphasizing progression-free survival and overall survival outcomes, and shares additional insights from the MIRAPOSA study.
Advertisement
Episodes in this series
- Recently, efficacy and safety data from the phase 3
FLAURA2 trial were published regarding the use of osimertinib alongside chemotherapy in the front-line setting. What are some important points to note from this study, and which patients might benefit from adding chemotherapy to osimertinib?- Please include a discussion of both PFS and OS observed in the FLAURA2 study
- Please discuss the adverse events observed in the monotherapy versus combination therapy group.
- The combination of amivantamab and a new 3rd generation EGFR TKI, lazertinib, had new front-line data presented at ESMO 2023, namely the
MARIPOSA trial. How was this study designed? - What were the results of the MARIPOSA trial, including efficacy and safety data, and how do you anticipate this data to ultimately impact front-line management of EGFR+ metastatic NSCLC with Ex19del or Ex21 L858R mutations?
- Despite FLAURA2 and MARIPOSA data now, what questions remain unanswered in the front-line management?
- How do you navigate treatment decisions for EGFR-mutated NSCLC patients with brain metastases, considering CNS penetration of the various EGFR-targeted therapies?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pharmacy Is a Practice, Not Just a Place
2
Beat the Heat: 10 Common Medication Culprits Causing Heat Intolerance
3
Yes, COVID-19 Is Still a Big Deal. Pharmacy Is the Tip of the Spear (and Needle)
4
FDA Fast Tracks First-in-Class TNFR2 Antibody as Chemotherapy-Free Strategy for Platinum-Resistant Ovarian Cancer
5